Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $19.355 million which beat the analyst consensus estimate of $8.518 million by 127.22 percent. This is a 1.13K percent increase over sales of $1.579 million the same period last year.